All Serina Therapeutics, Inc. Articles
Dog Days of Summer Produces Sharp Reversal In Stocks This Week- ( $FIG $GLD $MCD $META $MODD $NVDA Rise!)
As July closed and the dog days of summer arrived, U.S. equities faced a sharp reversal, punctuating several weeks of bullish momentum with a sobering dose of volatility—a direct consequence of new trade tensions and discouraging labor market reports. Index Performance All four major U.S. i...
Aug 01, 2025
View Article
Wall Street Delivers Choppy Session While Figma IPO Surged To Close Out July – ( $EPRX $FIG $META $MODD $ORCL $SER $RIO Rise!)
Wall Street delivered a choppy session to close July, as early gains faded with investors digesting a flurry of corporate results, inflation commentary, and trade policy developments. Major indices ended modestly lower, reflecting profit-taking and caution ahead of key economic data due Friday. ...
Jul 31, 2025
View Article
Cautious Investors Navigated Fed Fueled Volatile Session On Wednesday – ( $ADT $FTAI $GNRC $GOVX $HOOD $MCD $META $MODD $NVDA $ORCL $PLTR $WING Rise!)
Investors navigated a volatile session with major indices retreating from recent highs, as disappointment from earnings and cautious Federal Reserve guidance weighed on sentiment. Technology names fluctuated ahead of critical quarterly results, while macroeconomic headlines and fresh trade developm...
Jul 30, 2025
View Article
U.S. Stocks Reversed Course From Record Highs As Economic Data Painted A Nuanced Picture Tuesday – ( $GLD $GOVX $MCD $ORCL $RIO $SER Rise!)
Stocks pulled back as ma...
Jul 29, 2025
View Article
Nasdaq Dips, But Dow 30 & S&P 500 Power Forward On Tuesday – ( $ADT $GOVX $MCD $MODD $RIO $SER $SMMT $TSLA Rise!)
The major U.S. equity indices...
Jul 22, 2025
View Article
Record Stock Market Highs Continue On Monday – ( $GOVX $META $MODD $RIO $SMMT $TDOC Rise!)
Markets enter the heart of the earnings seas...
Jul 21, 2025
View Article
Wall Street Sets Record New Highs Amid Tech Surge, Tariff tensions, & Summer Earnings Momentum – ( $ASTS $GOVX $NVDA $PLTR $TSLA Rise!)
Equity markets have managed to shrug off trad...
Jul 18, 2025
View Article
Just Another Day Of Record Stock Market Highs Again On Thursday – ( $ADT $ASTS $EPRX $MCD $NVDA $ORCL $PLTR $RIO $SER $TDOC Rise!)
The U.S. equity markets marked another day o...
Jul 17, 2025
View Article
Serina Therapeutics: Optimizing Drug Delivery for the Future – ( $SER )
Serina Therapeutics (NYSE: SER) is positioning itself at the forefront of a new era in drug development, as highlighted in a recent corporate video titled "Rethinking Drug Development: Faster, Smarter, Strategic and reinforced by a series of strategic moves and partnerships. Rather than reinvent...
Jul 07, 2025
View Article
“Is The Beaten Down Biotech Sector The Smartest Bet In Today’s Volatile Market?” – ( $SER $XBI $IBB $PFE )
In the bustling digital amphitheater of Tribe Public’s latest CEO Presentation, the question of the hour was as sharp as it was timely: “Is the beaten down biotech sector the smartest bet in today’s volatile market?” With a flourish of slides and a dash of optimism, Steven A. Ledger, the...
Jun 16, 2025
View Article
Biotech Funding in 2025: A Wild Ride Through Uncertainty – ( $IBB $XBI $SER )
The biotech sector, long known for its rollercoaster fortunes, is currently experiencing a particularly stomach-churning drop. If the industry were an amusement park, the “Trump Policy Plunge” would be its latest and most daunting attraction—one that’s left investors clutching their wall...
Jun 09, 2025
View Article
Serina Therapeutics Strategically Adds Karuna Therapeutics’ CMO Dr. Stephen Brannan: A Power Move for CNS Innovation & Beyond ( $SER $BMY $TAK $NVS $LLY )
In the ever-evolving world of neuroscience drug development, on May 22, Serina Therapeutics (NYSE American: SER) announced that they have added a formidable new player to its Board of Directors: Dr. Stephen Brannan, a name that resonates with both gravitas and a touch of clinical stardust. Annou...
Jun 04, 2025
View Article
Serina Therapeutics (NYSE: SER) Secures JuvVentures (UK) Limited Equity Premium Financing To Advance Parkinson’s Disease Trials
Serina Therapeutics (NYSE: SER, $4.91) has secured the second $5 million tranche of a $10 million equity financing deal, strengthening its financial position as it prepares to advance its lead Parkinson's disease candidate, SER-252, into Phase 1 clinical trials in late 2025. In a financial maneuver ...
Feb 03, 2025
View Article
Stay Informed. Stay Competitive.
Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.
We value your privacy and will never share your information.
